Page last updated: 2024-11-07

spironolactone and Depressive Disorder, Major

spironolactone has been researched along with Depressive Disorder, Major in 5 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research Excerpts

ExcerptRelevanceReference
"The patient also had untreated Polycystic Ovarian Syndrome (PCOS)."2.41Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. ( Bauer, M; Carter, MS; Elman, S; Korenman, SG; Love, M; Rasgon, NL, 2002)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wingenfeld, K2
Kuehl, LK2
Dziobek, I1
Roepke, S1
Otte, C4
Hinkelmann, K4
Hellmann-Regen, J1
Mews, M1
Fleischer, J1
Heuser, I1
Moritz, S2
Yassouridis, A1
Jahn, H1
Wiedemann, K2
Kellner, M2
Botzenhardt, J1
Muhtz, C1
Rasgon, NL1
Carter, MS1
Elman, S1
Bauer, M1
Love, M1
Korenman, SG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Fludrocortisone on Information Processing in Healthy Female Volunteers[NCT01648998]Phase 140 participants (Actual)Interventional2012-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for spironolactone and Depressive Disorder, Major

ArticleYear
Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review.
    Current drug targets. Immune, endocrine and metabolic disorders, 2002, Volume: 2, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Therapy, Combinati

2002

Trials

3 trials available for spironolactone and Depressive Disorder, Major

ArticleYear
Effects of mineralocorticoid receptor blockade on empathy in patients with major depressive disorder.
    Cognitive, affective & behavioral neuroscience, 2016, Volume: 16, Issue:5

    Topics: Adult; Analysis of Variance; Cognition; Depressive Disorder, Major; Empathy; Female; Humans; Male; M

2016
Mineralocorticoid receptor function in depressed patients and healthy individuals.
    Progress in neuro-psychopharmacology & biological psychiatry, 2016, 11-03, Volume: 71

    Topics: Adult; Analysis of Variance; Area Under Curve; Case-Control Studies; Cross-Over Studies; Depressive

2016
Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Journal of psychiatric research, 2010, Volume: 44, Issue:6

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Diagn

2010

Other Studies

1 other study available for spironolactone and Depressive Disorder, Major

ArticleYear
Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study.
    Psychoneuroendocrinology, 2012, Volume: 37, Issue:5

    Topics: Adult; Antidepressive Agents; Attention; Cognition; Depressive Disorder, Major; Drug Therapy, Combin

2012